Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.45 |
| ▸ | HTR2C | P28335 | 18/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2673599 | 0.99 | HTR2A (0.44) | HTR2AHTR2CMEN1KMT2AL3MBTL1 | |
| SCHEMBL6371021 | 0.94 | HTR2A (0.39) | HTR2AHTR2CMEN1KMT2APKM | |
| Hydrochloric Acid SCHEMBL2674424 | 0.94 | HTR2A (0.39) | HTR2AHTR2CMEN1KMT2APKM | |
| Hydrochloric Acid SCHEMBL14142500 | 0.87 | PKM (0.39) | HTR2AHTR2CPKM | |
| SCHEMBL14142488 | 0.84 | KDM4E (0.43) | MEN1KMT2A | |
| SCHEMBL2674189 | 0.81 | MAPT (0.41) | MEN1KMT2A | |
| SCHEMBL11917225 | 0.81 | LOX (0.34) | MEN1KMT2A | |
| SCHEMBL2673669 | 0.80 | KMT2A (0.51) | KMT2AL3MBTL1 | |
| SCHEMBL6371270 | 0.77 | TSHR (0.41) | — | |
| SCHEMBL2672980 | 0.77 | KMT2A (0.47) | KMT2AL3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8173682-B2 | Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173682-B2 | Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202795-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HTR2A 484/4885HTR2C 1006/4885MEN1 2546/4885 |
| US-20070032489-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP3 | HTR2A 484/4885HTR2C 1006/4885MEN1 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.